Search: id:"swepub:oai:gup.ub.gu.se/144544" >
Two different durat...
-
Hansson, JohanKarolinska Institutet
(author)
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
- Article/chapterEnglish2011
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/144544
-
https://gup.ub.gu.se/publication/144544URI
-
https://doi.org/10.1016/S1470-2045(10)70288-6DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:122029343URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Adjuvant high-dose interferon alfa-2b improves relapse-free survival (RFS) in patients with high-risk melanoma, although benefits in overall survival are uncertain. Because of the toxic effects of high-dose regimens, intermediate doses are being explored. We investigated whether adjuvant therapy with intermediate-dose interferon alfa-2b for 1 or 2 years would improve outcomes in patients with stage IIB-IIC or III resected cutaneous melanoma.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Aamdal, Steinar
(author)
-
Bastholt, Lars
(author)
-
Brandberg, YvonneKarolinska Institutet
(author)
-
Hernberg, Micaela
(author)
-
Nilsson, Bo
(author)
-
Stierner, Ulrika,1952Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology(Swepub:gu)xstiul
(author)
-
von der Maase, Hans
(author)
-
Karolinska InstitutetInstitutionen för kliniska vetenskaper, Avdelningen för onkologi
(creator_code:org_t)
Related titles
-
In:The lancet oncology12:2, s. 144-521474-5488
Internet link
Find in a library
To the university's database